Precision medicine and COVID-19: Importance of host genome profiling
Apstrakt
Introduction: The clinical picture and the course of the disease in COVID-19 patients, caused by coronavirus SARS-CoV-2, vary from asymptomatic to fatal outcome. As the same agent cause the disease, the
individual genomic profile of the patient could contribute to better understanding of this phenomenon.
The current knowledge about genetic markers responsible for a wide range of clinical pictures, as well
as possible application of individualized treatment, will be presented.
Methods: Variantsin genesresponsible for predisposition and response to SARS-CoV-2 infection, pharmacogenetic variantsrelated to drugs used in the treatment of COVID-19, nutrigenetic markersin genes
relevant for the metabolism of the micronutrients(vitamin D,selenium and zinc) were investigated using
GWAS, PCR and sequencing. Genotype data were extracted from database previously obtained using
TruSight One Gene Panel (Illumina).
Results: Eleven pharmacogenomics markers in 7 pharmacogenes relevant for COVID...-19 treatment and
10 variants affecting the structure and/or function of proteinsimportant forsusceptibility and resistance
to SARS-CoV-2 infection were identified. Several variants in genes related to micronutrients were associated with severe COVID-19. Moreover, GWAS detected a significant genetic signal associated with
COVID-19 related pneumonia.
Conclusion: Multidisciplinary approach, modern sequencing technologies, comprehensive studies with
well-characterized patients’groups, as well as the design of robust bioinformatics tools, enable identification of novel human genetic markers associated with COVID-19. Newly gained knowledge will empower the development of the targeted therapy, as well as the implementation of
nutrigenomics/pharmacogenomics, leading to the application of precision medicine in the treatment of
COVID-19 patients.
Ključne reči:
COVID-19 / precision medicine / pharmacogenomics / nutrigenomics / GWASIzvor:
CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia, 2023, 30-30Izdavač:
- Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
Finansiranje / projekti:
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200042 (Univerzitet u Beogradu, Institut za molekularnu genetiku i genetičko inženjerstvo) (RS-MESTD-inst-2020-200042)
Institucija/grupa
Institut za molekularnu genetiku i genetičko inženjerstvoTY - CONF AU - Zukić, Branka PY - 2023 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/2109 AB - Introduction: The clinical picture and the course of the disease in COVID-19 patients, caused by coronavirus SARS-CoV-2, vary from asymptomatic to fatal outcome. As the same agent cause the disease, the individual genomic profile of the patient could contribute to better understanding of this phenomenon. The current knowledge about genetic markers responsible for a wide range of clinical pictures, as well as possible application of individualized treatment, will be presented. Methods: Variantsin genesresponsible for predisposition and response to SARS-CoV-2 infection, pharmacogenetic variantsrelated to drugs used in the treatment of COVID-19, nutrigenetic markersin genes relevant for the metabolism of the micronutrients(vitamin D,selenium and zinc) were investigated using GWAS, PCR and sequencing. Genotype data were extracted from database previously obtained using TruSight One Gene Panel (Illumina). Results: Eleven pharmacogenomics markers in 7 pharmacogenes relevant for COVID-19 treatment and 10 variants affecting the structure and/or function of proteinsimportant forsusceptibility and resistance to SARS-CoV-2 infection were identified. Several variants in genes related to micronutrients were associated with severe COVID-19. Moreover, GWAS detected a significant genetic signal associated with COVID-19 related pneumonia. Conclusion: Multidisciplinary approach, modern sequencing technologies, comprehensive studies with well-characterized patients’groups, as well as the design of robust bioinformatics tools, enable identification of novel human genetic markers associated with COVID-19. Newly gained knowledge will empower the development of the targeted therapy, as well as the implementation of nutrigenomics/pharmacogenomics, leading to the application of precision medicine in the treatment of COVID-19 patients. PB - Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade C3 - CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia T1 - Precision medicine and COVID-19: Importance of host genome profiling EP - 30 SP - 30 UR - https://hdl.handle.net/21.15107/rcub_imagine_2109 ER -
@conference{ author = "Zukić, Branka", year = "2023", abstract = "Introduction: The clinical picture and the course of the disease in COVID-19 patients, caused by coronavirus SARS-CoV-2, vary from asymptomatic to fatal outcome. As the same agent cause the disease, the individual genomic profile of the patient could contribute to better understanding of this phenomenon. The current knowledge about genetic markers responsible for a wide range of clinical pictures, as well as possible application of individualized treatment, will be presented. Methods: Variantsin genesresponsible for predisposition and response to SARS-CoV-2 infection, pharmacogenetic variantsrelated to drugs used in the treatment of COVID-19, nutrigenetic markersin genes relevant for the metabolism of the micronutrients(vitamin D,selenium and zinc) were investigated using GWAS, PCR and sequencing. Genotype data were extracted from database previously obtained using TruSight One Gene Panel (Illumina). Results: Eleven pharmacogenomics markers in 7 pharmacogenes relevant for COVID-19 treatment and 10 variants affecting the structure and/or function of proteinsimportant forsusceptibility and resistance to SARS-CoV-2 infection were identified. Several variants in genes related to micronutrients were associated with severe COVID-19. Moreover, GWAS detected a significant genetic signal associated with COVID-19 related pneumonia. Conclusion: Multidisciplinary approach, modern sequencing technologies, comprehensive studies with well-characterized patients’groups, as well as the design of robust bioinformatics tools, enable identification of novel human genetic markers associated with COVID-19. Newly gained knowledge will empower the development of the targeted therapy, as well as the implementation of nutrigenomics/pharmacogenomics, leading to the application of precision medicine in the treatment of COVID-19 patients.", publisher = "Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade", journal = "CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia", title = "Precision medicine and COVID-19: Importance of host genome profiling", pages = "30-30", url = "https://hdl.handle.net/21.15107/rcub_imagine_2109" }
Zukić, B.. (2023). Precision medicine and COVID-19: Importance of host genome profiling. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade., 30-30. https://hdl.handle.net/21.15107/rcub_imagine_2109
Zukić B. Precision medicine and COVID-19: Importance of host genome profiling. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia. 2023;:30-30. https://hdl.handle.net/21.15107/rcub_imagine_2109 .
Zukić, Branka, "Precision medicine and COVID-19: Importance of host genome profiling" in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia (2023):30-30, https://hdl.handle.net/21.15107/rcub_imagine_2109 .